Sales of the firm's cell therapy franchise grew modestly in the fourth quarter amid competing product launches and overall slow uptake within the class.

Sartorius Stedim Biotech SA / Key word (s): Dividend Board of Directors of Sartorius Stedim Biotech resolves to propose dividend of 0.69 euros per share to Annual Shareholders’ Meeting 07-Feb-2025 ...

To find the stage, you’ll need medical testing. This may include a chest x-ray, CT scan, or other tests. Treatment depends on the type of cutaneous T-cell lymphoma you have and the stage of the cancer ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Ozone therapy is a controversial alternative medicine practice that involves using ozone gas to fight disease. Currently, there is not enough evidence to conclude it is effective or safe for ...

Autolus Therapeutics' obe-cel, branded Aucatzyl, is the first CAR-T therapy approved without a ... while limiting the overactivation of any one CAR-T cell. This apparently improves the molecule ...

The National Health Service (NHS) has approved a groundbreaking £1.65 million treatment for sickle cell disease in England, offering patients a promising 96.6% cure rate. The new therapy, hailed as a ...

Thus, there is an urgent need for advanced therapies for patients suffering from severe and refractory autoimmune diseases, and researchers have considered cell therapy as potentially curative ...